Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Other Non Operating Income (2016 - 2025)

IGC Pharma has reported Other Non Operating Income over the past 16 years, most recently at $1.1 million for Q3 2025.

  • Quarterly Other Non Operating Income rose 2406.98% to $1.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Sep 2025, up 3932.56% year-over-year, with the annual reading at $325000.0 for FY2025, N/A changed from the prior year.
  • Other Non Operating Income was $1.1 million for Q3 2025 at IGC Pharma, up from $306000.0 in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $1.1 million in Q3 2025 and troughed at -$136000.0 in Q1 2024.
  • The 5-year median for Other Non Operating Income is $32000.0 (2023), against an average of $118000.0.
  • Year-over-year, Other Non Operating Income plummeted 525.0% in 2024 and then soared 2406.98% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at $4000.0 in 2021, then surged by 625.0% to $29000.0 in 2022, then grew by 10.34% to $32000.0 in 2023, then soared by 53.12% to $49000.0 in 2024, then surged by 2100.0% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Other Non Operating Income are $1.1 million (Q3 2025), $306000.0 (Q2 2025), and $215000.0 (Q1 2025).